Furthermore, the cluster with the strongest proapoptotic effect (decreased viability) after inhibitor treatment did not differ with regard to cause of AML (secondary versus de novo), cytogenetics, AML cell differentiation (FAB classification, CD34 expression), karyotype, FLT3-ITD or NPM1 mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.